423
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis

, , ORCID Icon, &
Pages 789-796 | Received 11 Jan 2021, Accepted 02 Apr 2021, Published online: 27 Sep 2021
 

Abstract

Purpose

We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs.

Methods

irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018.

Results

Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs.

Conclusion

These data underscore the needs for tailored irAE diagnostic and management pathways.

Previous presentations

Presented in part at the National Comprehensive Cancer Network Annual Conference, Orlando, Florida, March 20–22, 2019 (Poster Presentation).

Declaration of interest

J.N.: Research Funding: Merck, AstraZeneca; Consulting: AstraZeneca, Bristol Myers-Squibb, Roche/Genentech; Honoraria: AstraZeneca, Bristol Myers-Squibb

Additional information

Funding

Monica Nicosia, PhD, Nicosia Medical Writer LLC, and Mary Costantino, PhD provided medical editing and writing support, funded by Humana Inc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.